Circulating Tumor Cells and Cancer Stem Cells Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region

Description

Innovations in Biotechnology and Increased Research Activities Drive Market Growth

Circulating tumor cells and cancer stem cells, two critical elements in understanding cancer mechanisms and finding potential cures, are gaining significant attention in the global healthcare landscape. These cells play a pivotal role in detecting metastasis and assessing the risk of cancer relapse. As a result, the global circulating tumor cells and cancer stem cells market is poised for rapid growth, driven by advancements in biotechnology and biomedical engineering.

Key Factors Driving Market Growth

Rising Prevalence of Musculoskeletal Disorders: Musculoskeletal disorders are becoming increasingly common, leading to a growing demand for braces and support systems that can correct these issues. Factors such as heavy lifting, sports injuries, and accidents contribute to the rising incidence of these disorders.

Geriatric Population: The elderly are more susceptible to musculoskeletal illnesses due to bone and ligament weakening, leading to a higher risk of muscle and bone injuries. The increasing geriatric population is a significant driver of market growth.

Technological Advancements: Manufacturers are focusing on developing technologically advanced braces and support devices, presenting lucrative opportunities for growth. These innovations aim to provide more effective solutions for musculoskeletal issues.

Global Research Activities: Cancer is a leading cause of mortality and morbidity worldwide, with about 14 million people impacted annually, according to WHO. This has led to a rapid increase in research activities, fueling the development of circulating tumor cells and cancer stem cells as critical areas of study.

Government Initiatives: Government bodies and organizations are taking initiatives to fund research activities, which is a major factor driving the growth of the global circulating tumor cells and cancer stem cells market.

Oncology Screening and Treatment Monitoring: Increasing demand for oncology screening, diagnosis, and treatment monitoring to track disease progression among patients is contributing to market growth.

Challenges Impacting Market Growth

Lack of Awareness: Limited awareness about the availability and benefits of advanced braces and support systems, coupled with the high cost of these devices, hinders market growth.

Preference for Conventional Products: In some regions, especially underdeveloped or developing areas, end-users prefer conventional products over technologically sophisticated solutions, affecting the adoption of advanced braces.

Limitations in Certain Patients: Patients with excessive muscle mass due to underlying conditions like Edema may not benefit from bracing-mediated treatment. This restricts the patient pool and affects the sales of leg braces.

Low Awareness and Reliance on Painkillers: Limited awareness about musculoskeletal conditions and a tendency to rely on painkillers instead of braces and support systems contribute to restrained market growth.

Regional Market Insights

North America: The region leads the global market due to its developed economy, strong healthcare sector, significant funding for oncology research, high cancer prevalence rates, and favorable government initiatives.

Asia Pacific: This region is expected to witness substantial growth during the forecast period, driven by increasing awareness, developments in research and healthcare sectors, and rising cancer prevalence.

Key Players in the Market

Several key players are contributing to the global circulating tumor cells and cancer stem cells market, including QIAGEN Hannover, AVIVA Biosciences, Epic Sciences, ApoCell, Cynvenio Biosystems, Fluxion Biosciences, Rarecells, Janssen Diagnostics, LLC, CellTraffix Inc., Silicon Biosystems, and Advanced Cell Diagnostics, Inc., among others.

Key Segments of Circulating Tumor Cells and Cancer Stem Cells Industry Research

Based on technology type

Cell enrichment
Detection
CTC Analysis

Based on Application types

Biomarkers
Tumorigenesis
Stem cell research
Others

Region:

North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East and Africa

1. Executive Summary

1.1. Global Circulating Tumor Cells and Cancer Stem Cells Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2023
1.5. Analyst Recommendations

2. Market Overview

2.1. Market Definitions and Segmentations
2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter's Five Forces Analysis
2.5. COVID-19 Impact Analysis
- 2.5.1. Supply
- 2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
- 2.7.1. World Economic Projections
2.8. PESTLE Analysis

3. Global Circulating Tumor Cells and Cancer Stem Cells Market Outlook, 2018 - 2031

3.1. Global Circulating Tumor Cells and Cancer Stem Cells Market Outlook, by Based on Technology Type, Value (US$ Bn), 2018 - 2031
- 3.1.1. Key Highlights
  - 3.1.1.1. Cell enrichment
  - 3.1.1.2. Detection
  - 3.1.1.3. CTC Analysis
3.2. Global Circulating Tumor Cells and Cancer Stem Cells Market Outlook, by Application Type, Value (US$ Bn), 2018 - 2031
- 3.2.1. Key Highlights
  - 3.2.1.1. Biomarkers
  - 3.2.1.2. Tumorigenesis
  - 3.2.1.3. Stem cell research
  - 3.2.1.4. Others
3.3. Global Circulating Tumor Cells and Cancer Stem Cells Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
- 3.3.1. Key Highlights
  - 3.3.1.1. North America
  - 3.3.1.2. Europe
  - 3.3.1.3. Asia Pacific
  - 3.3.1.4. Latin America
  - 3.3.1.5. Middle East & Africa

4. North America Circulating Tumor Cells and Cancer Stem Cells Market Outlook, 2018 - 2031

4.1. North America Circulating Tumor Cells and Cancer Stem Cells Market Outlook, by Based on Technology Type, Value (US$ Bn), 2018 - 2031
- 4.1.1. Key Highlights
  - 4.1.1.1. Cell enrichment
  - 4.1.1.2. Detection
  - 4.1.1.3. CTC Analysis
4.2. North America Circulating Tumor Cells and Cancer Stem Cells Market Outlook, by Application Type, Value (US$ Bn), 2018 - 2031
- 4.2.1. Key Highlights
  - 4.2.1.1. Biomarkers
  - 4.2.1.2. Tumorigenesis
  - 4.2.1.3. Stem cell research
  - 4.2.1.4. Others
- 4.2.2. BPS Analysis/Market Attractiveness Analysis
4.3. North America Circulating Tumor Cells and Cancer Stem Cells Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 4.3.1. Key Highlights
  - 4.3.1.1. U.S. Circulating Tumor Cells and Cancer Stem Cells Market by Based on Technology Type, Value (US$ Bn), 2018 - 2031
  - 4.3.1.2. U.S. Circulating Tumor Cells and Cancer Stem Cells Market by Application Type, Value (US$ Bn), 2018 - 2031
  - 4.3.1.3. Canada Circulating Tumor Cells and Cancer Stem Cells Market by Based on Technology Type, Value (US$ Bn), 2018 - 2031
  - 4.3.1.4. Canada Circulating Tumor Cells and Cancer Stem Cells Market by Application Type, Value (US$ Bn), 2018 - 2031
- 4.3.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Circulating Tumor Cells and Cancer Stem Cells Market Outlook, 2018 - 2031

5.1. Europe Circulating Tumor Cells and Cancer Stem Cells Market Outlook, by Based on Technology Type, Value (US$ Bn), 2018 - 2031
- 5.1.1. Key Highlights
  - 5.1.1.1. Cell enrichment
  - 5.1.1.2. Detection
  - 5.1.1.3. CTC Analysis
5.2. Europe Circulating Tumor Cells and Cancer Stem Cells Market Outlook, by Application Type, Value (US$ Bn), 2018 - 2031
- 5.2.1. Key Highlights
  - 5.2.1.1. Biomarkers
  - 5.2.1.2. Tumorigenesis
  - 5.2.1.3. Stem cell research
  - 5.2.1.4. Others
- 5.2.2. BPS Analysis/Market Attractiveness Analysis
5.3. Europe Circulating Tumor Cells and Cancer Stem Cells Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 5.3.1. Key Highlights
  - 5.3.1.1. Germany Circulating Tumor Cells and Cancer Stem Cells Market by Based on Technology Type, Value (US$ Bn), 2018 - 2031
  - 5.3.1.2. Germany Circulating Tumor Cells and Cancer Stem Cells Market by Application Type, Value (US$ Bn), 2018 - 2031
  - 5.3.1.3. U.K. Circulating Tumor Cells and Cancer Stem Cells Market by Based on Technology Type, Value (US$ Bn), 2018 - 2031
  - 5.3.1.4. U.K. Circulating Tumor Cells and Cancer Stem Cells Market by Application Type, Value (US$ Bn), 2018 - 2031
  - 5.3.1.5. France Circulating Tumor Cells and Cancer Stem Cells Market by Based on Technology Type, Value (US$ Bn), 2018 - 2031
  - 5.3.1.6. France Circulating Tumor Cells and Cancer Stem Cells Market by Application Type, Value (US$ Bn), 2018 - 2031
  - 5.3.1.7. Italy Circulating Tumor Cells and Cancer Stem Cells Market by Based on Technology Type, Value (US$ Bn), 2018 - 2031
  - 5.3.1.8. Italy Circulating Tumor Cells and Cancer Stem Cells Market by Application Type, Value (US$ Bn), 2018 - 2031
  - 5.3.1.9. Turkey Circulating Tumor Cells and Cancer Stem Cells Market by Based on Technology Type, Value (US$ Bn), 2018 - 2031
  - 5.3.1.10. Turkey Circulating Tumor Cells and Cancer Stem Cells Market by Application Type, Value (US$ Bn), 2018 - 2031
  - 5.3.1.11. Russia Circulating Tumor Cells and Cancer Stem Cells Market by Based on Technology Type, Value (US$ Bn), 2018 - 2031
  - 5.3.1.12. Russia Circulating Tumor Cells and Cancer Stem Cells Market by Application Type, Value (US$ Bn), 2018 - 2031
  - 5.3.1.13. Rest of Europe Circulating Tumor Cells and Cancer Stem Cells Market by Based on Technology Type, Value (US$ Bn), 2018 - 2031
  - 5.3.1.14. Rest of Europe Circulating Tumor Cells and Cancer Stem Cells Market by Application Type, Value (US$ Bn), 2018 - 2031
- 5.3.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Circulating Tumor Cells and Cancer Stem Cells Market Outlook, 2018 - 2031

6.1. Asia Pacific Circulating Tumor Cells and Cancer Stem Cells Market Outlook, by Based on Technology Type, Value (US$ Bn), 2018 - 2031
- 6.1.1. Key Highlights
  - 6.1.1.1. Cell enrichment
  - 6.1.1.2. Detection
  - 6.1.1.3. CTC Analysis
6.2. Asia Pacific Circulating Tumor Cells and Cancer Stem Cells Market Outlook, by Application Type, Value (US$ Bn), 2018 - 2031
- 6.2.1. Key Highlights
  - 6.2.1.1. Biomarkers
  - 6.2.1.2. Tumorigenesis
  - 6.2.1.3. Stem cell research
  - 6.2.1.4. Others
- 6.2.2. Others BPS Analysis/Market Attractiveness Analysis
6.3. Asia Pacific Circulating Tumor Cells and Cancer Stem Cells Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 6.3.1. Key Highlights
  - 6.3.1.1. China Circulating Tumor Cells and Cancer Stem Cells Market by Based on Technology Type, Value (US$ Bn), 2018 - 2031
  - 6.3.1.2. China Circulating Tumor Cells and Cancer Stem Cells Market by Application Type, Value (US$ Bn), 2018 - 2031
  - 6.3.1.3. Japan Circulating Tumor Cells and Cancer Stem Cells Market by Based on Technology Type, Value (US$ Bn), 2018 - 2031
  - 6.3.1.4. Japan Circulating Tumor Cells and Cancer Stem Cells Market by Application Type, Value (US$ Bn), 2018 - 2031
  - 6.3.1.5. South Korea Circulating Tumor Cells and Cancer Stem Cells Market by Based on Technology Type, Value (US$ Bn), 2018 - 2031
  - 6.3.1.6. South Korea Circulating Tumor Cells and Cancer Stem Cells Market by Application Type, Value (US$ Bn), 2018 - 2031
  - 6.3.1.7. India Circulating Tumor Cells and Cancer Stem Cells Market by Based on Technology Type, Value (US$ Bn), 2018 - 2031
  - 6.3.1.8. India Circulating Tumor Cells and Cancer Stem Cells Market by Application Type, Value (US$ Bn), 2018 - 2031
  - 6.3.1.9. Southeast Asia Circulating Tumor Cells and Cancer Stem Cells Market by Based on Technology Type, Value (US$ Bn), 2018 - 2031
  - 6.3.1.10. Southeast Asia Circulating Tumor Cells and Cancer Stem Cells Market by Application Type, Value (US$ Bn), 2018 - 2031
  - 6.3.1.11. Rest of Asia Pacific Circulating Tumor Cells and Cancer Stem Cells Market by Based on Technology Type, Value (US$ Bn), 2018 - 2031
  - 6.3.1.12. Rest of Asia Pacific Circulating Tumor Cells and Cancer Stem Cells Market by Application Type, Value (US$ Bn), 2018 - 2031
- 6.3.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Circulating Tumor Cells and Cancer Stem Cells Market Outlook, 2018 - 2031

7.1. Latin America Circulating Tumor Cells and Cancer Stem Cells Market Outlook, by Based on Technology Type, Value (US$ Bn), 2018 - 2031
- 7.1.1. Key Highlights
  - 7.1.1.1. Cell enrichment
  - 7.1.1.2. Detection
  - 7.1.1.3. CTC Analysis
7.2. Latin America Circulating Tumor Cells and Cancer Stem Cells Market Outlook, by Application Type, Value (US$ Bn), 2018 - 2031
- 7.2.2. BPS Analysis/Market Attractiveness Analysis
7.3. Latin America Circulating Tumor Cells and Cancer Stem Cells Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 7.3.1. Key Highlights
  - 7.3.1.1. Brazil Circulating Tumor Cells and Cancer Stem Cells Market by Based on Technology Type, Value (US$ Bn), 2018 - 2031
  - 7.3.1.2. Brazil Circulating Tumor Cells and Cancer Stem Cells Market by Application Type, Value (US$ Bn), 2018 - 2031
  - 7.3.1.3. Mexico Circulating Tumor Cells and Cancer Stem Cells Market by Based on Technology Type, Value (US$ Bn), 2018 - 2031
  - 7.3.1.4. Mexico Circulating Tumor Cells and Cancer Stem Cells Market by Application Type, Value (US$ Bn), 2018 - 2031
  - 7.3.1.5. Argentina Circulating Tumor Cells and Cancer Stem Cells Market by Based on Technology Type, Value (US$ Bn), 2018 - 2031
  - 7.3.1.6. Argentina Circulating Tumor Cells and Cancer Stem Cells Market by Application Type, Value (US$ Bn), 2018 - 2031
  - 7.3.1.7. Rest of Latin America Circulating Tumor Cells and Cancer Stem Cells Market by Based on Technology Type, Value (US$ Bn), 2018 - 2031
  - 7.3.1.8. Rest of Latin America Circulating Tumor Cells and Cancer Stem Cells Market by Application Type, Value (US$ Bn), 2018 - 2031
- 7.3.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Circulating Tumor Cells and Cancer Stem Cells Market Outlook, 2018 - 2031

8.1. Middle East & Africa Circulating Tumor Cells and Cancer Stem Cells Market Outlook, by Based on Technology Type, Value (US$ Bn), 2018 - 2031
- 8.1.1. Key Highlights
  - 8.1.1.1. Cell enrichment
  - 8.1.1.2. Detection
  - 8.1.1.3. CTC Analysis
8.2. Middle East & Africa Circulating Tumor Cells and Cancer Stem Cells Market Outlook, by Application Type, Value (US$ Bn), 2018 - 2031
- 8.2.1. Key Highlights
  - 8.2.1.1. Biomarkers
  - 8.2.1.2. Tumorigenesis
  - 8.2.1.3. Stem cell research
  - 8.2.1.4. Others
- 8.2.2. BPS Analysis/Market Attractiveness Analysis
8.3. Middle East & Africa Circulating Tumor Cells and Cancer Stem Cells Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 8.3.1. Key Highlights
  - 8.3.1.1. GCC Circulating Tumor Cells and Cancer Stem Cells Market by Based on Technology Type, Value (US$ Bn), 2018 - 2031
  - 8.3.1.2. GCC Circulating Tumor Cells and Cancer Stem Cells Market by Application Type, Value (US$ Bn), 2018 - 2031
  - 8.3.1.3. South Africa Circulating Tumor Cells and Cancer Stem Cells Market by Based on Technology Type, Value (US$ Bn), 2018 - 2031
  - 8.3.1.4. South Africa Circulating Tumor Cells and Cancer Stem Cells Market by Application Type, Value (US$ Bn), 2018 - 2031
  - 8.3.1.5. Egypt Circulating Tumor Cells and Cancer Stem Cells Market by Based on Technology Type, Value (US$ Bn), 2018 - 2031
  - 8.3.1.6. Egypt Circulating Tumor Cells and Cancer Stem Cells Market by Application Type, Value (US$ Bn), 2018 - 2031
  - 8.3.1.7. Nigeria Circulating Tumor Cells and Cancer Stem Cells Market by Based on Technology Type, Value (US$ Bn), 2018 - 2031
  - 8.3.1.8. Nigeria Circulating Tumor Cells and Cancer Stem Cells Market by Application Type, Value (US$ Bn), 2018 - 2031
  - 8.3.1.9. Rest of Middle East & Africa Circulating Tumor Cells and Cancer Stem Cells Market by Based on Technology Type, Value (US$ Bn), 2018 - 2031
  - 8.3.1.10. Rest of Middle East & Africa Circulating Tumor Cells and Cancer Stem Cells Market by Application Type, Value (US$ Bn), 2018 - 2031
- 8.3.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

9.1. Manufacturer vs by Application Type Heatmap
9.2. Company Market Share Analysis, 2023
9.3. Competitive Dashboard
9.4. Company Profiles
- 9.4.1. QIAGEN Hannover
  - 9.4.1.1. Company Overview
  - 9.4.1.2. Product Portfolio
  - 9.4.1.3. Financial Overview
  - 9.4.1.4. Business Strategies and Development
- 9.4.2. AVIVA Biosciences
  - 9.4.2.1. Company Overview
  - 9.4.2.2. Product Portfolio
  - 9.4.2.3. Financial Overview
  - 9.4.2.4. Business Strategies and Development
- 9.4.3. Epic Sciences
  - 9.4.3.1. Company Overview
  - 9.4.3.2. Product Portfolio
  - 9.4.3.3. Financial Overview
  - 9.4.3.4. Business Strategies and Development
- 9.4.4. ApoCell
  - 9.4.4.1. Company Overview
  - 9.4.4.2. Product Portfolio
  - 9.4.4.3. Financial Overview
  - 9.4.4.4. Business Strategies and Development
- 9.4.5. Cynvenio Biosystems
  - 9.4.5.1. Company Overview
  - 9.4.5.2. Product Portfolio
  - 9.4.5.3. Financial Overview
  - 9.4.5.4. Business Strategies and Development
- 9.4.6. Fluxion Biosciences
  - 9.4.6.1. Company Overview
  - 9.4.6.2. Product Portfolio
  - 9.4.6.3. Financial Overview
  - 9.4.6.4. Business Strategies and Development
- 9.4.7. Rarecells
  - 9.4.7.1. Company Overview
  - 9.4.7.2. Product Portfolio
  - 9.4.7.3. Financial Overview
  - 9.4.7.4. Business Strategies and Development
- 9.4.8. Janssen Diagnostics
  - 9.4.8.1. Company Overview
  - 9.4.8.2. Product Portfolio
  - 9.4.8.3. Financial Overview
  - 9.4.8.4. Business Strategies and Development
- 9.4.9. CellTraffix Inc.
  - 9.4.9.1. Company Overview
  - 9.4.9.2. Product Portfolio
  - 9.4.9.3. Financial Overview
  - 9.4.9.4. Business Strategies and Development
- 9.4.10. Silicon Biosystems
  - 9.4.10.1. Company Overview
  - 9.4.10.2. Product Portfolio
  - 9.4.10.3. Financial Overview
  - 9.4.10.4. Business Strategies and Development
- 9.4.11. Advanced Cell Diagnostics, Inc.
  - 9.4.11.1. Company Overview
  - 9.4.11.2. Product Portfolio
  - 9.4.11.3. Financial Overview
  - 9.4.11.4. Business Strategies and Development

10. Appendix

10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations